Suffolk Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Suffolk Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-31,916	Closed	-$9M	–	153
2015 Q1	$9M	Sell	31,916 -43,691	-58%	-$9.46M	1.06%	36
2014 Q4	$11.8M	Buy	75,607 +13,078	+21%	+$2.42M	1.44%	30
2014 Q3	$14.8M	Buy	62,529 +20,381	+48%	+$5.2M	1.84%	5
2014 Q2	$9.97M	Buy	42,148 +26,026	+161%	+$6.86M	1.21%	34
2014 Q1	$5.32M	Sell	16,122 -25,078	-61%	-$8.46M	0.66%	56
2013 Q4	$2.81M	Buy	+41,200	New	+$2.38M	0.35%	94

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Suffolk Capital Management's ICPT Position: Q2 2015 in Review

Suffolk Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2015, closing a stake of 31,916 shares — an estimated $9M sold.

Suffolk Capital Management first reported a position in ICPT in Q4 2013 and held it in 6 quarters. The position peaked at $14.8M in Q3 2014. 191 funds tracked by Wall St. Rank hold ICPT as of Q2 2015.

Suffolk Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Suffolk Capital Management sold 31,916 Intercept Pharmaceuticals, Inc. shares in Q2 2015, an estimated $9M.
Suffolk Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2013 and held it in 6 quarters.
Suffolk Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $14.8M in Q3 2014.
191 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2015.

Based on Suffolk Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.